Sponsor
M.D. Anderson Cancer Center
Status
Completed
ClinicalTrials.gov ID
For more information, see ClinicalTrials.gov NCT03407001
This early phase I trial studies how well contrast enhanced ultrasound with sulfur hexafluoride lipid microspheres (Lumason) works in detecting liver cancer in participants with cirrhosis. Contrast enhanced-ultrasounds use contrast agents, such as Lumason, that are injected into a vein in order to help certain organs and tissues show up more clearly on scans. Contrast enhanced ultrasound with Lumason may help doctors more easily find liver cancer compared to ultrasounds without contrast agent.
Intervention
Sulfur Hexafluoride Lipid Microspheres, Ultrasound, Contrast-Enhanced Ultrasound
Condition
Cirrhosis
Investigators
Ott Le